000728432 000__ 04131cam\a2200409Ii\4500
000728432 001__ 728432
000728432 005__ 20230306141012.0
000728432 006__ m\\\\\o\\d\\\\\\\\
000728432 007__ cr\cn\nnnunnun
000728432 008__ 150803s2015\\\\sz\a\\\\ob\\\\000\0\eng\d
000728432 020__ $$a9783319204338$$qelectronic book
000728432 020__ $$a3319204335$$qelectronic book
000728432 020__ $$z9783319204321
000728432 035__ $$aSP(OCoLC)ocn915343747
000728432 035__ $$aSP(OCoLC)915343747
000728432 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dN$T$$dGW5XE$$dIDEBK$$dYDXCP$$dAZU
000728432 049__ $$aISEA
000728432 050_4 $$aRC632.D87
000728432 08204 $$a616.3997$$223
000728432 24500 $$aCombination therapy in dyslipidemia$$h[electronic resource] /$$cMaciej Banach, editor.
000728432 264_1 $$aCham, Switzerland :$$bSpringer,$$c2015.
000728432 300__ $$a1 online resource :$$billustrations
000728432 336__ $$atext$$btxt$$2rdacontent
000728432 337__ $$acomputer$$bc$$2rdamedia
000728432 338__ $$aonline resource$$bcr$$2rdacarrier
000728432 504__ $$aIncludes bibliographical references.
000728432 5050_ $$aForeword -- Statins and bile acid resins -- is there a place for such a combination? -- Statins and fibrates -- should it be recommended? -- Statins and ezetimibe -- doubts or bright future? -- Statins and niacin -- the end of residual risk therapy? -- Statins and omega-3 fatty acids -- what more do we need? -- Statins and CETP inhibitors -- anacetrapib and evacetrapib -- the last hope? -- Statins and mipomersen -- the issue of tolerability? -- Statins and lomitapide -- a suitable response for HoFH -- Statins and PCSK9 inhibitors -- defining the correct patients -- Other possible drug combination for dyslipidaemia -- Statins and nutraceuticals/functional food -- Could be they combined? -- Lipid lowering therapy and apheresis -- indications and outcomes -- Combination of lipid lowering agents with antihypertensive drugs -- a joint fight against the two most important risk factors? -- Not only dyslipidaemia therapy -- the time for polypills -- Drug Evaluation: Fenofibrate + simvastatin for the treatment of dyslipidemia: When and for whom? -- Drug Evaluation: Olmesartan medoxomil + rosuvastatin for the treatment of dyslipidemia and concomitant risk factors: A chance for better compliance? -- Conclusions and Take Home Message.
000728432 506__ $$aAccess limited to authorized users.
000728432 520__ $$aComprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia, and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia. Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP), and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.
000728432 650_0 $$aDyslipoproteinemias.
000728432 650_0 $$aHyperlipidemia.
000728432 650_0 $$aChemotherapy, Combination.
000728432 7001_ $$aBanach, Maciej,$$eeditor.
000728432 852__ $$bebk
000728432 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-20433-8$$zOnline Access$$91397441.1
000728432 909CO $$ooai:library.usi.edu:728432$$pGLOBAL_SET
000728432 980__ $$aEBOOK
000728432 980__ $$aBIB
000728432 982__ $$aEbook
000728432 983__ $$aOnline
000728432 994__ $$a92$$bISE